Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tesevatinib (XL647) in NSCLC post-erlotinib/gefitinib
NCT00522145Phase 2Completed
- Sponsor
- Kadmon
- Start
- May 2007
- Primary completion
- Oct 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tesevatinib in non-small cell lung cancer (NSCLC), sponsored by Kadmon. Started May 2007; status: completed.
02
Drugs
tesevatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00522145.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00522145.